News

Pharmaceutical Technology on MSN1d
FDA grants expanded access to ImmunityBio’s Anktiva for lymphopenia
Anktiva is designed to address BCG-unresponsive bladder cancer through its mechanism as an interleukin-15 superagonist.
The Pharma Letter2h
FDA clears Bayer’s Nubeqa in earlier-stage prostate cancer
The American medicines regulator has approved Bayer’s Nubeqa (darolutamide) for broader use in patients with metastatic ...
U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer
U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer ...
Pharmaceutical Technology on MSN2d
CirCode Biomed gains clearance from FDA for RNA drug HM2002
HM2002 offers advantages due to its composition of circular RNAs, which provide improved stability and low immunogenicity.
FDA won’t approve COVID shot for healthy, non-elderly population
The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials ...
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides’ Dr. Diwan
SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the ...
PharmExec12d
FDA Clears Investigational New Drug Application for Ascletis’ Oral IL-17 Inhibitor in Mild-to-Moderate Plaque Psoriasis
Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.
Ophthalmology Times13d
FDA grants Breakthrough Therapy Designation for Tinlarebant
Belite Bio recently announced the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the ...
Pharmabiz1d
CirCode Biomed gets US FDA clearance for IND application of HM2002, the world's first circular RNA drug being administrated in patients
CirCode Biomed gets US FDA clearance for IND application of HM2002, the world's first circular RNA drug being administrated in patients: Shanghai, China Monday, June 2, 2025, 18:0 ...